Trial Profile

A randomized, open-label, multicenter Phase II study designed to evaluate the safety and efficacy of selinexor versus physician's choice (PC) in patients with Myelofibrosis who had at least six months of treatment with a JAK1/2 inhibitor

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Aug 2021 According to an Antengene Corporation media release, this trial will be conducted at 15 centers across China, including the primary trial center the First Affiliated Hospital Soochow University, and will enroll approximately 20 patients in total.
23 Aug 2021 According to an Antengene Corporation media release, the China National Medical Products Administration has approved this Phase II study of selinexor for the treatment of patients with myelofibrosis (MF).
09 Jul 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com